Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Rep Nakagawa Casts Doubt on 80% Generic Target
August 28, 2015
- MHLW Panel Recommends Creation of Database on Rare Cancers by Type
August 28, 2015
- MHLW Mulls Ordering Pfizer to Improve Biz Operations over ADR Reporting
August 28, 2015
- Panel OKs Medical Subsidy for Harvoni, Monthly Copay Up to 20,000 Yen
August 28, 2015
- Commentary: Spiking Drug Prices Behind Harvoni Pricing Spat at Chuikyo
August 28, 2015
- PFSB to Monitor Drug Companies’ Promotional Activities at 20 Selected Medical Facilities
August 28, 2015
- PFSB to Request Budget of 10.7 Billion Yen in FY2016 to Improve Environments for Development of Innovative Drugs, Quality of Generics
August 28, 2015
- Health Service Bureau Seeks 469.1 Billion Yen in FY2016 Budget, 120.2 Billion Yen for Intractable Diseases
August 28, 2015
- Health Policy Bureau Seeks 193.6 Billion Yen in FY2016 Budget, 6.6 Billion Yen for Clinical Research Promotion
August 28, 2015
- FPMAJ Wants Continuation of Innovation Premium, No Market Price-Based Price Revision in 2017: Chuikyo Hearings
August 27, 2015
- Chuikyo’s HTA Panel Issues Interim Report, Appraisal Results to Be Used to Re-Price Selected Listed Drugs
August 27, 2015
- Development Projects, Regulatory Filings Increasing Thanks to Innovation Premium: PhRMA, EFPIA
August 27, 2015
- MHLW Seeks 30.7 Trillion Yen in FY2016 Budget, 104.3 Billion for Drug, Healthcare Initiatives
August 27, 2015
- Chuikyo Reps Trade Barbs over Pricing of Harvoni, Listing OK'ed by a Whisker
August 27, 2015
- Chuikyo OKs Listing of Harvoni, Peak Sales Put at 119 Billion Yen in 2nd Year
August 26, 2015
- 4 Pharma Groups Welcome MHLW’s “Comprehensive Strategy”
August 25, 2015
- MHLW OKs New Indications for Remicade, Other Products
August 25, 2015
- MHLW Reveals Outline of “Comprehensive Strategy” for Pharma Sector
August 25, 2015
- Drug Pricing Tomorrow: MHLW Councilor Takeda Says NHI Drug Prices Should Mirror Evaluation of Individual Firms
August 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for August 10 - August 23
August 24, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…